NCT04987931View on ClinicalTrials.gov

Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

August 20, 2021

Primary Completion Date

October 11, 2021

Study Completion Date

October 11, 2021

Conditions

Breast Cancer

Interventions

DRUG

Talazoparib

This retrospective chart review study focuses on patients with HER2- ABC with gBRCA1/2m initiating talazoparib on or after October 16, 2018 and ≥18 years of age at initiation of talazoparib.

Trial Locations (1)

10017

Pfizer Inc, New York